Anti-tumor activity in preclinical models utilizing a conditional bispecific redirected activation molecule (COBRA) targeting Her2

被引：1
|
作者：
Stringer, Bradley
Chouitar, Johara
Cerbone, Jacqualine
Fortin, Sarah
Ainbinder, Alina
Kysilovsky, Cassie
Scott, Brittany
Banerjee, Antara
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB063
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A novel EGFR x HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation
    Li, Zhuolin
    Shang, Chengzhang
    An, Gao
    Guo, Chaoshe
    An, W. Frank
    Yang, Yi
    CANCER RESEARCH, 2024, 84 (06)
  • [32] CAR T-Cells Targeting the EDB Splice Variant of Fibronectin Have Potent Anti-Tumor and Anti-Vasculature Activity in Preclinical Solid Tumor Models
    Wagner, Jessica
    Wickman, Elizabeth
    Shaw, Timothy I.
    Zhou, Xin
    Krenciute, Giedre
    Zhang, Jinghui
    Gottschalk, Stephen
    MOLECULAR THERAPY, 2020, 28 (04) : 16 - 16
  • [33] An anti-idiotypic HER2 vaccine can reverse immunological tolerance to HER2 and induce anti-tumor immunity in huHER2 female transgenic mice
    Ladjemi, M. Z.
    Corgnac, S.
    Morisseau, S.
    Robert, B.
    Mollevi, C.
    Chares, T.
    Jacot, W.
    Pelegrin, A.
    Navarro-Teulon, I.
    EJC SUPPLEMENTS, 2008, 6 (12): : 188 - 188
  • [34] Evaluating preclinical efficacy of anti-HER2 drug combinations using ER+/HER2 mutant models
    Kavuri, S. M.
    Devarakonda, V.
    Williams, L. C.
    Seker, S.
    Lei, J. T.
    Singh, P.
    Han, A.
    Anurag, M.
    Holloway, K. R.
    Welm, A. L.
    Ellis, M. J.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] Evaluating preclinical efficacy of anti-HER2 drug combinations using ER+/HER2 mutant models
    Devarakonda, Vaishnavi
    Williams, LaTerrica
    Seker, Sinem
    Lei, Jonathan T.
    Singh, Purba
    Han, Airi
    Anurag, Meenakshi
    Holloway, Kimberly R.
    Weim, Alana L.
    Ellis, Matthew J.
    Kavuri, Shyam M.
    CANCER RESEARCH, 2019, 79 (13)
  • [36] Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
    Hung Huynh
    Richard Ong
    Khee Chee Soo
    Angiogenesis, 2012, 15 : 59 - 70
  • [37] Anti-tumor activity of Debio 0123 in combination with sacituzumab govitecan in preclinical models of breast cancer
    Piggott, Luke
    Imedio, Esteban Rodrigo
    Staehli, Francesco
    CANCER RESEARCH, 2024, 84 (06)
  • [38] Dual immune checkpoint inhibition enhances the anti-tumor activity of trastuzumab deruxtecan in preclinical models
    Jenkins, Liam
    Kazlauskas, Laura
    Wilson, Matt
    Hammond, Scott A.
    Proia, Theresa
    Mettetal, Jerome
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
    Huynh, Hung
    Ong, Richard
    Soo, Khee Chee
    ANGIOGENESIS, 2012, 15 (01) : 59 - 70
  • [40] Dual MTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
    Garcia-Garcia, C.
    Ibrahim, Y. H.
    Serra, V.
    Calvo, M. T.
    Aura, C.
    Perez, J.
    Rommel, C.
    Tabernero, J.
    Baselga, J.
    Scaltriti, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S192 - S192
12345